Acadia Pharmaceuticals (ACAD) Cash from Operations Growth (1y) (2011 - 2026)
Acadia Pharmaceuticals (ACAD) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 158.60% |
| 10 | Acadia Pharmaceuticals | 4.38 Bn | 3.53 Bn | 243.27 Mn | 67.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 67.20% |
| Dec 31, 2025 | -220.68% |
| Sep 30, 2025 | 17.46% |
| Jun 30, 2025 | 155.69% |
| Mar 31, 2025 | -30.11% |
| Dec 31, 2024 | -52.71% |
| Sep 30, 2024 | 207.28% |
| Jun 30, 2024 | 205.00% |
| Mar 31, 2024 | 262.15% |
| Dec 31, 2023 | 457.97% |
| Sep 30, 2023 | -8,009.35% |
| Jun 30, 2023 | 162.48% |
| Mar 31, 2023 | 76.51% |
| Dec 31, 2022 | -3.17% |
| Sep 30, 2022 | 95.74% |
| Jun 30, 2022 | 48.18% |
| Mar 31, 2022 | -26.90% |
| Dec 31, 2021 | 15.89% |
| Sep 30, 2021 | 25.13% |
| Jun 30, 2021 | 31.33% |